S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Data Published in Human Gene Therapy Clinical Development Support Safety of AGTC's AAV Vector Manufacturing Process|
|Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform|
|Solid Q3 2014 Results Reinforces Advantage's Enviable Growth Position (2014/11/13)|
|ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis Disease Activity, in Addition to Previously Shown Kidney Disease Improvements|
|ChemoCentryx Reports Third Quarter 2014 Financial Results and Provides Corporate Update|
|ChemoCentryx Releases Phase III SHIELD 4 Clinical Results in Patients With Crohn's Disease|
|ChemoCentryx to Hold Third Quarter 2014 Financial Results Conference Call on Wednesday, November 5, 2014|
|ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective in CCR9 Blockade in Phase I Study|
|BioMarin Announces Third Quarter 2014 Financial Results|
|ChemoCentryx to Present at Two Upcoming Investor Conferences|
Click above to view more mutual fund data and stats for aav - Advantage Oil & Gas Ltd.